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Abstract:. Somatic mutation analysis and evaluation of microsatellite instability (MSI) have 
become mandatory for selecting personalized therapy strategies for advanced colorectal cancer 
and are not available as routine methods in Paraguay.  The aims of this study were to analyze 
the molecular profile as well as the microsatellite status in a series of advanced colorectal 
patients from two public hospitals from Paraguay, to introduce these methodologies in the 
routine practice to guide the therapeutic decisions. Methods: 36 patients diagnosed with 
advanced colorectal from two referent public hospitals from Paraguay were recruited from May 
2017 to February 2018. Sequenom Mass spectrometry, Oncocarta Panel V.1 was applied to 
analyze the mutational profile from FFPE samples. The microsatellite status was tested by 
immunohistochemistry. Results: The mean age of the patients was 52 years with a range from 
20 to 74 years. Eighty three percent of the patients included in the study has advanced-stage 
tumors at the moment of the diagnosis. Sixteen patients (44.4%) were wild-type for all the 
oncogene regions analysed with the Oncocarta panel. 32 hot-spots mutations on seven 
oncogenes, among 20 patients (55.6 %), were identified, including KRAS, NRAS, BRAF, PI3KCA, 
FGFR, EGFR and PDGFRA. Five patients (14%) presented microsatellite instability. Conclusions: 
The immunohistochemical study for microsatellite status and the molecular profile analysis 
through Sequenom Mass Spectometry are feasible and useful methods, due to identify  those 
patients  candidates for  targeted therapies and for the budgetary calculations of the National 





Colorectal cancer (CRC) is the third most common cancer worldwide in terms of incidence, but 
also the second in terms of mortality with over 1.8 million new CRC cases and 881,000 deaths 
estimated to occur in 2018 [1].The highest CRC incidence rates are found in some parts of Europe 
(including Hungary, Slovenia, Slovakia, the Netherlands and Norway), Australia/New Zealand, 
Northern America and Eastern Asia. As an extent of westernization, CRC now ranks as the top 
five cancer in Latin-America, being the second and third leading cause of cancer death in South 
America and the Caribbean, respectively [2]. Paraguay occupies the position 19th within Latin-
American countries with an incidence of 15 and 12.7 per 100.000 in men and women, 
respectively, and a mortality of 9 and 7.5 per 100.000 in men and women, respectively [1].  
 
CRC in Latin-American countries is diagnosed at an advanced stage of the disease in almost 80% 
of cases, especially in those related with low socio-economic conditions [3]. Metastatic disease 
initially is not suitable for potentially curative resection. Therefore, advanced target-therapies, 
such as monoclonal antibodies (bevacizumab) or proteins (aflibercept) against vascular 
endothelial growth factor (VEGF), and against the epidermal growth factor receptor (EGFR), 
respectively, in combination with chemotherapy, should be considered in patients with 
metastatic CRC (mCRC), since they improve the outcome of mCRC patients [4-7]. However, the 
high costs associated with these targeted-therapies limits their application in developing 
countries, including Paraguay [8, 9]. 
 
The gold standard of the therapeutic strategy includes a multidisciplinary management and an 
early approach to the disease. For the advanced disease, chemotherapy associated with 
targeted therapies selected according to the pathological and molecular profile of the tumor, 
increase the median overall survival (OS) to around 30 months. Factors which may have 
contributed to this improvement in the OS includes: i) continuous and more exhaustive follow 
up, ii) improvements in the efficacy of systemic therapies, iii) inclusion of biomarker-based 




Somatic mutation analysis has become mandatory for selecting personalized therapies for CRC. 
Mutation profiling of the RAS/BRAF pathway could guide the selection of patients with potential 
benefit from anti-EGFR therapies [5, 11, 12]. Mutations in KRAS or NRAS (expanded RAS analysis) 
predict a lack of response to EGFR-targeting monoclonal antibodies. Moreover, this targeted 
therapy has a detrimental effect in patients with RAS-mutant tumours, specifically when 
combined with an oxaliplatin-based cytotoxic backbone [13-15]. BRAF mutations (mainly V600E) 
are found in around 8%-12% of patients with mCRC included in clinical trials and are almost 
exclusively non-overlapping with other RAS mutations. BRAF mutations are a significant negative 
prognostic marker for patients with mCRC [16]. Moreover, two meta-analyses demonstrated 
that the benefit of EGFR antibody therapies was greater in patients with RAS wild-type/BRAF 
wild-type tumours than in those with RAS wild-type/BRAF-mutant tumours [11, 17]. Methods 
for molecular testing include Sanger sequencing, pyrosequencing, next generation sequencing 
(NGS) technology and mass spectrometry with different spectrum of advantages /disadvantages 
[18]. The mass spectrometry technique, matrix-assisted laser desorption/ionization-time of 
flight, is a cost-effective method that has been used to assess point mutations across different 
solid tumors [19, 20]. The Sequenom MassARRAY technology, in combination with a commercial 
kit called OncoCarta v1.0 was used to screen 238 somatic mutations across 19 oncogenes 
exploring somatic changes in oncogenes with known responses or resistance-targeted therapy. 
 
The evaluation of microsatellite instability (MSI) in CRC through the immunohistochemical (IHC) 
study for mismatch repair proteins (MMR) expression has become mandatory in daily practice 
for various reasons. MMR deficiency is the main characteristic of the CMS1 group of the latest 
CRC consensus molecular classification [21]. This group of tumors is linked to specific 
clinicopathologic features with lower rates of response to chemotherapy and shorter disease-
free survival periods after treatment. About 15% of CRC arise through the MSI pathway and most 
of these tumors are sporadic [22]. However, the IHC study for MMR proteins is recommended 
for the detection of the hereditary non-polyposis CRC syndrome (Lynch syndrome) accounting 
for 1% to 5% of all the cases [23]. Moreover, MSI is the only predictive biomarker approved by 
the FDA for the immune checkpoint blockade inhibitors therapy with pembrolizumab and 
nivolumab in gastrointestinal tumours. MMR deficient mCRC, represents approximately 4% of 
all mCRC cases and is characterized by very high levels of mutations. Extensive basic research 
and clinical trial efforts are underway to identify the optimal therapy combinations that are 
needed for this CRC subset.[24, 25] 
 
 The aim of this study was to characterize the underlying molecular changes associated to CRC 
in the Paraguayan population. For this purpose, we evaluated the histopathological features, 
the presence of common somatic mutations and the MMR proteins status in a cohort of 
prospectively recruited Paraguayan patients, in order to incorporate these determinations in the 




Materials and Methods: 
 
Patient selection and data collection 
 
The design of the study was exploratory and prospective. A total of 36 consecutive and non-
related CRC patients were recruited from May 2017 to February 2018 at the Medical Oncology 
Units from two public hospitals in Paraguay: Hospital de Clinicas (HC) and Instituto Nacional del 
Cancer (INCAN). Patient eligibility criteria included clinical and histological diagnoses of 
advanced CRC chemo-naive or in progression to a first line chemotherapy for the advanced 
disease, ECOG 0 or 1, and potential candidates to receive chemotherapy in combination with 
target therapies according to the clinical guidelines [26]. 
 
Clinical and pathological information, including age, sex, tumor location, histological grade and 
treatments were collected (Table 1). All study subjects gave written informed consent, and the 
study was approved by the Biomedical Research Institute INCLIVA and the Hospital de Clínicas-
Paraguay Ethics Committee. 
 
Formalin-fixed paraffin-embedded (FFPE) tissues were evaluated for their tumor content, and 
sections containing more than 30% tumor cells were selected by a dedicated pathologist. 
Genomic DNA was isolated from 4 unstained sections of 20 μm and diluted to a final solution of 
10ng/μl. This was done using the QIAamp DNA FFPE tissue kit (QIAGEN). DNA concentration was 





Immunohistochemistry (IHC) assays were performed in the 36 colorectal cancer patients as we 
previously described [27].  The primary antibodies used were MLH1 (clone IR079, dilution 1:100, 
Dako), MSH2 (clone IR085, dilution 1:100, Dako), PMS2 (clone IR087, dilution 1:100, Dako) and 
MSH6 (clone IR086, dilution 1:100, Dako). 
   
Tumours were considered positive if they present only nuclear staining, with or without 
cytoplasmic staining. Peritumoral lymphocytes, stromal cells and non-neoplastic epithelial cells 
were used as internal control. Only the complete loss of nuclear staining with positive internal 
control was classified as loss of miss-match repair (MMR) protein expression and was considered 
as evidence of microsatellite status instability (MSI). Normal expression was defined as the 
presence of nuclear staining in tumor cells, irrespective of the intensity.  
 
Sequenom MassARRAY somatic mutation genotyping 
 
The Sequenom MassARRAY and OncoCarta Panel v1.0 were used following the manufacturer's 
protocol (Sequenom, San Diego, CA, USA; (http://agenabio.com/oncocarta-panel)) as previously 
described [19]. The panel consisted of 24 multiplex assays capable of detecting 238 mutations 
in 19 oncogenes. This procedure was a rapid, cost-effective method of identifying key cancer 
driving mutations across a large number of samples because it avoided complex bioinformatic 
analyses and assays were performed within two days. The amount of DNA added to the 
polymerase chain reaction was 20 ng per reaction. DNA was amplified using the OncoCarta PCR 
primer pools. Unincorporated nucleotides were inactivated by shrimp alkaline phosphatase 
(SAP), and a single base extension reaction was performed using extension primers that 
hybridize immediately adjacent to the mutations and a custom mixture of nucleotides. Salts 
were removed by the addition of a cation exchange resin. Multiplexed reactions were spotted 
onto SpectroCHIP II arrays, and DNA fragments were resolved by MALDI-TOF on the Compact 
Mass Spectrometer (Sequenom, San Diego, CA). An additional customized panel was used for 
some of the samples as a quality control. Details regarding genes and hot-spot mutations 




Statistical analyses were carried out by IBM SPSS v 20.0. A p value of less than 0.05 was 
considered statistically significant. Comparison between clinical and pathologic patient’s 
characteristics was done using the Chi squared test, the Fisher’s exact test or the Wilcoxon rank 
test for qualitative and quantitative variables respectively prior assessment of normality using 
the Shapiro-Wilk test. Tumor-specific survival (TSS) was calculated from the time of diagnosis to 
the time of death because of tumor-related causes or until the last known follow-up. Survival 
curves were performed by using the Kaplan-Meier analysis compared thought the log-rank test. 
Multivariate regression analysis was carried using Cox proportional hazards models with 
stepwise selection, including those variables significantly correlated with the survival probability 
on the univariate analysis. SPSS v20.0 was used to analyze the results.  
 
Genomic data were analyzed using the Sequenom MassARRAY Typer Analyser 4.0 Software to 
visualize the mass spectra for mutations and to determine the frequency of mutant and wild-
type alleles. The lower thresholds for mutation detection have been reported between 5-10% 
[28]. In order to reduce putative false positives, we set the threshold at 10%. More specifically, 
only mutations with frequencies higher than 10% were taken as positive results. Mutations were 
manually reviewed by use of visual and raw spectrum patterns. Two different personnel in the 
laboratory scored mutations, and no discrepancies were observed. Analyses were performed 
using IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp (IBM Corp. Released 
2010). 
 
Mutational Waterfall plot of the patients dataset was performed through visualization of the 
plot by cBioportal-OncoPrimer v1.18.0  (www.cbioportal.org/OncoPrimer) and   Llolliplots have 
been draw with cBioportal-Mutation Mapper v1.18.0 (www.cbioportal.org/MutationMapper) 




Patient characteristics  
Seven patients (19%) from Hospital de Clínicas and 29 patients (81%) from INCAN were included 
in the study. The mean age of the patients was 52 years with a range from 20 to 74 years. 
Twenty-three patients were males (63.9%) and 13 were females (36.1%). Eighty three percent 
of the patients included in the study has advanced-stage tumors at the moment of the diagnosis 
with more tumors located in the left (61%, 22 cases) than in the right side (39%, 14 patients). All 
the patients received a first line chemotherapy. In addition, 9 of the patients received 
bevacizumab treatment.  
 Clinical characteristics of the patients are shown in Table 1 and Table supplementary 2.  
 
Mutational analysis 
The molecular characterization analysis showed 16 patients (44.4%) wild-type for all the 
oncogene regions analysed with the Oncocarta panel. We have been able to identified 32 hot-
spots mutations on seven oncogenes among 20 patients (55.6 %). A total of 16 different 
oncogenic mutations were identified. Considering that the threshold of mutation detection with 
the technology applied is 10%, we observed a median average mutation load of 22.44% among 
all the samples, ranging from 8.5% up to 53,7%. 
The most frequently mutated genes were KRAS in 11 tumours (7 with p.G12D, 3 with p.G12V 
and one with p.G13D), PIK3CA in 8 tumours (5 mutations in the hot-spot p.H1047R/Y, one in 
p.G.1049R, p.E542K and p.R88Q respectively), NRAS (all in p.G13D) and BRAF (2 in p.V600E, one 
in p.D594V and one in p.G469R) in 4 tumours. Seven out of 20 patients have two or more 
mutations. Four patients have co-occurrence mutations in KRAS and PIK3CA. Strikingly, two of 
the KRAS/PIK3CA mutated tumours carried also another mutation in NRAS (p.G13D). Low 
frequently mutated genes were EGFR, PDGFRA and FGFR1 and variations in these genes 
appeared in co-ocurrence with mutations in the most frequently mutated genes mentioned 
above (see Figure 2).  Plot with number of patients with mutations, frequency of mutated genes 
and co-ocurrences are presented in Figure 2. Full details of protein products of the mutated 
genes, specific mutations detected, its localisation in protein domain and their frequency are 
presented in Figure 3.  
 
Immunohistochemistry of miss-matched repair (MMR) proteins 
Five patients (14%) presented MSI. Three of them were younger than 50 years old and had family 
history of CRC. The other two MSI cases were 54 and 57 years old without any family history of 
cancer. Two patients presented lost of MSH2 and MSH6 expression (a 27 years old female and 
41 years old one male). Clinical, pathological and molecular characteristics of patients with MMR 
protein expression alterations are shown in Table2 and Figure 4. 
 
Clinical correlations of patients and survival data 
There was a significant correlation between tumor location (right vs left) and age (> or < 50 years 
old) (p<.0.05). All cases of tumors located in the right colon were patients >50 years old. No 
other correlations between the clinical characteristics (gender, age, MSS status or mutation 
profile) were found significant. 
 
The mean TSS at the moment of the analysis was 23.6 months (12-35 months). No differences 
were found in TSS according to the mutational status, gender, MSS status or the treatment 
administered (chemotherapy +/-bevacizumab). Survival curves are represented in Figure 5. 
However, a better survival trend to signification can be observed in relation with the following 
clinicopathological characteristics: patients without any mutation (candidates to anti-EGFR 
therapies), male patients, left side colon tumours, patients treated with antiangiogenics and 
patients with preserved MMR protein expression.  
IHC and molecular profile analysis provided relevant information for a personalized medicine 
approach for all the cases. In our series, 45% of the patients had RAS wild-type tumors that could 
benefit from anti-EGFR therapies. Moreover, five patients with MSI profile, could benefit from 
immunotherapy with checkpoint inhibitors such as pembrolizumab or nivolumab.[31, 32] 
   
Discussion:  
Colorectal cancer (CRC) incidence rates vary widely, with 8-fold and 6-fold variations by world 
regions for colon and rectal cancer, respectively. Therefore, CRC could be considered a marker 
of socioeconomic development, as is seen in countries undergoing a major development 
transition, where incidence rates tend to rise uniformly with the increasing Human Development 
Index (HDI). [1] These rises in incidence—particularly the generational changes detected in most 
age-period-cohort analyses— point to the influence of dietary patterns, obesity and lifestyle 
factors. However, mortality rates are declining in more developed countries due to 
improvements in survival through the adoption of best practices in cancer prevention, early 
diagnosis through screening approaches and personalized treatments.[33] Actually, molecular 
characterization has become a useful and mandatory tool for a personalised medicine approach 
in CRC [10], however, screening programs are not available in all developing countries. 
 
The situation in Paraguay is alarming, with a CRC incidence rising during the last 20 years for 
both sexes from a population rate /100.000 of 3.66 and 2.87 for males and females respectively 
in 1998 to 5.51 for males and 4.88 for females in 2015 [1]. Thus, there is an urgent need for the 
implementation of effective strategies at primary, secondary and third levels of prevention that 
could improve the results in Paraguay. For secondary prevention, the first steps have been made 
during 2018 with the implementation of CRC screening, however, it is still in a very initial stage. 
Regarding patients with advanced CRC, targeted therapies associated with chemotherapy 
improve the outcomes. [34, 35] Nevertheless, their high costs limit their availability and use in 
Paraguay. Therefore, precision medicine through molecular testing is needed due to identify 
those patients candidates for  targeted therapies and for the budgetary calculations of the 
National Health Plans.  
The aim of our study was to characterize the underlying molecular changes associated to CRC in 
the Paraguayan population through MassARRAY technology, in order to incorporate these 
determinations into the Paraguayan Health Care System to guide therapeutics decisions. The 
Sequenom MassARRAY technology, in combination with a commercial kit called OncoCarta v1.0 
was used to screen 238 somatic mutations across 19 oncogenes exploring somatic changes in 
oncogenes with known responses or resistance-targeted therapy. This methodology makes it 
possible for a medium-sized laboratory to analyse multiple key hotspot mutations rapidly (within 
3 days) and without complex bioinformatics analysis tools at a moderate price. Although the 
limited number of patients included, our work is the first published data of advanced CRC in 
Paraguay. We found 45% of patients that could benefit from anti-EGFR therapies according to 
their mutational profile (RAS wild-type). Although, more than 80% of the patients recruited were 
diagnosed with advanced disease, we detected just above 55% of them with oncogenic 
mutations. From the 19 oncogenes evaluated, only 7 had mutations (including KRAS, NRAS, 
BRAF, PI3KCA, PDGFRA, EGFR and FGFR), which is in line with data reported in the COSMIC 
database and in previous studies. The largest CRC series of patients analysed by MassARRAY 
OncocartaTM Panel included 239, 254 and 2299 patients [20, 28, 36, 37]. In a previous study from 
our group [19] mutations were detected in 48 out of 75 CRC cases (64.2%) using this technology. 
Specifically, mutations were found mainly in the KRAS, PIK3CA and KIT genes. In our experience, 
the MassARRAY technology in combination with the OncoCarta Panel successfully detected 
frequent cancer mutations in degraded DNA isolated from FFPE samples and covers up to 95% 
of known druggable markers. Thus, it provides an efficient mutation screening for clinical 
research trials and with high concordance with NGS technologies. Our results confirmed that 
MassARRAY technology is a rapid and effective method for identifying key cancer-driving 
mutations across a large number of samples, which allows for a more appropriate selection for 
personalized therapies, and could be a cost-effective method for the molecular profiling in 
Paraguay.  
 
MSI in mCRC has a global frequency of 4%. As  mentioned before, the analysis of MMR is relevant 
for the diagnosis of hereditary syndromes, as well as for the identification of biomarkers that 
would guide immunotherapy with immune checkpoint blockade inhibitors [38]. The analysis of 
MMR can be done through IHC and PCR techniques, both methods are available in Paraguay. 
Recently, checkpoint inhibitors have been included into the national drugs bank.  In our series, 
we detected MSI in five cases, two of them showing loss of MSH2 and MSH6, a pattern highly 
suggestive of Lynch syndrome. Those cases should be comprehensively analysed in genetic 
counselling units, in order to evaluate the presence of germline mutations. In our series, the 
young average age of presentation (just over 50 years), and the presence of MMR proteins loss 
of MSH2 and MSH6 in two cases (5%) highlights the importance of the urgent implementation 
of genetic counselling units in Paraguay.  
 
Despite the low number of patients included in the study we were able to draw the mutation 
profile of CRC patients in Paraguay. In addition, the study would provide relevant clinical and 
molecular information to be included in Public Oncology Reference Hospitals of Paraguay, as 
well as the usefulness of Sequenom MassARRAY technology for the molecular profiling and the 
MSI testing  to guide the therapeutics to guide  the treatment of advanced  CRC disease. 
 
 
Table and Figure legends: 
 
Table 1: Clinical and pathological characteristics of patients diagnosed with colorectal cancer.  
 
Table 2: Clinical, pathological and molecular characteristics of patients with mismatch repair 
protein expression loss. 
 
Figure 1: Demographic characteristics of the serie. a) Percentage of patients recruited from the 
two different participating centres: INCAN: Instituto Nacional del Cáncer HC: Hospital de Clínicas, 
b) Percentage of patients with right (green) and left (blue) location of tumor lesions, c) 
Distribution of men and women among the samples analyzed, d) Distribution of patients 
according to the age at the moment of diagnosis > or < 50 years old. 
 
Figure 2: Mutational Waterfall plot of the patient’s dataset. Data has been obtained by 
analyzing the OncocartaTM v1.0 panel (MassARRAYR System by Agena BioscienceTM). 
Visualization of the plot by cBioportal-OncoPrimer v1.18.0 [29, 30] 
(www.cbioportal.org/OncoPrimer). Colored squares mean the type of alteration detected: 
green indicates missense mutation whereas black identifies truncating mutation. All grey 
squares identify one patient; when they are without any other color means that no alterations 
are present in the sample. 
 
Figure 3: Mapping of Mutations detected in seven oncogenes. Lolliplots have been draw with 
cBioportal-Mutation Mapper v1.18.0 (www.cbioportal.org/MutationMapper) [29, 30]. The plot 
identifies the different domains in each respective protein. The nature of the mutations and its 
position is shown. The number of times each mutation has been detected is shown with the left 
scale and is represented by the height of dot.  A) KRAS , b) PIK3CA, c) NRAS, d) BRAF, e) EFGR, f) 
PDGFRA and g) FGFR1. 
 
Figure 4: Immunohistochemical study of mismatch repair proteins expression. Complete loss 
of nuclear staining for MSH6 and MSH2 in tumor cells, with positive internal control in stromal 
lymphocytes and fibroblasts (A: MSH6 40X, D: MSH2 40X) Retained MLH1 and PMS2 nuclear 
expression in tumor cells (B: MLH1 40X, C: PMS2 40X).  
 
Figure 5: Kaplan Meier curves of tumor specific survival (TSS) of the colorectal cancer patients. 
A) Tumor specific survival of the all series. B) Tumor specific survival according to the tumor 
location (left vs right) C) Tumor specific survival according to the gender (males vs females). D) 
Tumor specific survival according to the treatment administered. (chemotherapy + 
antiangiogenics vs chemotherapy alone). E) Tumor specific survival according to the mutation 
profile (mutated/no mutated). F) Tumor specific survival according to the mutation profile: KRAS 
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 Table 1- Clinical and pathological characteristics of patients diagnosed with colorectal cancer 





















Mutation profile (%) 














2 ( 5,7) 










 1st Line Treatments administered (%) 
5-FU + oxaliplatin/irinotecan 






Table 2. Clinical, pathological and molecular characteristics of patients with MMR protein 
expression alterations. 
Gender Age Location Molecular 
profile 






Female 57 right 
BRAF 
(11.0%) PMS2 / MLH1 lost - 
Female 27 left 
KRAS 
(25.7%) PMS2 / MLH1 lost + 
Female 27 left 
KRAS 
(29.0%) 
MSH6 lost and MSH2 
heterogeneous 
expression + 
Male 41 left WT MSH2 / MSH6 lost + 
Male 54 right WT PMS2 / MLH1 lost unknown 
 
Table supplementary 2:  Clinical and Molecular characteristics of patients. 
 
LAB CODE CENTRE GENDER AGE YO 
TUMOR 
LOCATION GENE MUT % MMR EXPRESSION 
MTCYD1 INCAN Male < 50 Right    ALL WT   Normal 
MT-CYD2 INCAN Female < 50 Left KRAS G12D 29,50%  MSH6 & MSH2 (-) 
MT-CYD3 INCAN Female ≥50 Left BRAF V600E 17,30% Normal 
MT-CYD4 INCAN Male < 50 Left PIK3CA G1049R 11.00% NV 
MT-CYD5 INCAN Female < 50 Left KRAS G12D 25,70% PMS2 & MLH1(-) 
MT-CYD6 HC Male ≥50 Left KRAS G12V 31.20% Normal 
MT-CYD7 HC Female < 50 Left KRAS G13D 25,60% Normal 
MT-CYD8 HC Male < 50 Left KRAS G12D 24,20% Normal 





MT-CYD10 INCAN Male < 50 Left BRAF V600E 18,80% Normal 





MT-CYD12 HC Female ≥50 Right BRAF D594V|G 11,20%  PMS2 & MLH1 (-) 
MT-CYD13 HC Male ≥50 Right NRAS G13D 25,60% Normal 
  
    
PIK3CA H1047R 11,80%   
  
    
KRAS G12D 26,80%   
MT-CYD14 HC Female ≥50 Right FGFR1 S125L 42,50% Normal 
  
    
NRAS G13D 25,90%   
MT-CYD15 HC Male < 50 Right KRAS G12V 16,40% Normal 










MT-CYD18 INCAN Female < 50 Left KRAS G12D 28,10% NV 
  
    
PIK3CA H1047R 15,10%   
MT-CYD19 INCAN Male < 50 Left BRAF G469R 24,90% Normal 





MT-CYD21 INCAN Female ≥50 Left PIK3CA R88Q 39,50% Normal 
  
    
PIK3CA H1047Y 13,60%   
 
  
    
PDGFRA D1071N 10,10%   





MT-CYD23 INCAN Male ≥50 Right EGFR D770_N771insG 33,80% Normal 
  
    
NRAS G13D 10,40%   
  
    
PDGFRA D842V 53,70%   





MT-CYD25 INCAN Female < 50 Left PIK3CA H1047R 11,10% Normal 
  
    
KRAS G12V 8,50%   
  
    
NRAS G13D 9,50%   
  
    
EGFR 
L747_S752del, 
P753S 11,20%   





MT-CYD27 INCAN Male ≥50 Left KRAS G12D 34,00% Normal 
  
    
PIK3CA E542K 15,30%   
MT-CYD28 INCAN Male ≥50 Right PIK3CA H1047Y 11,70% Normal 




PMS2 & MLH1(-) 





MT-CYD31 INCAN Male ≥50 Right KRAS G12D 41,50% Normal 




















MT-CYD36 INCAN Male ≥50 Left 
 
ALL WT   Normal 
